Background: Graft-versus-host disease (GvHD) remains the major toxicity of allogeneic bone marrow transplantation (BMT). In the acute form of the disease, the differential diagnosis includes viral rash and drug eruptions. Methods: We report two patients with chronic myeloid leukemia submitted to allogeneic BMT who developed a severe form of acute cutaneous GvHD, with clinical and histological pictures mimicking toxic epidermal necrolysis (TEN). Results: We found a predominance of peripheral CD8+ T lymphocytes and, at the same time, studying the cellular profile of the blister fluid, just in the beginning of blister eruption, we also found a high proportion of CD8+ T lymphocytes, mainly CD8+CD57–. Conclusion: These data are in agreement with previous reports of the presence of CD8+ T cells in the blister fluid of patients with TEN, further emphasizing similar immunoinflammatory pathways in both diseases.

Ferrara JLM, Deeg HJ: Graft-versus-host disease. N Engl J Med 1991;324:667–674.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED: Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825–828.
Aractingi S, Chosidow O: Cutaneous graft-versus-host disease. Arch Dermatol 1998;134:602–612.
Johnson ML, Farmer ER: Graft-versus-host reactions in dermatology. J Am Acad Dermatol 1998;38:369–392.
Villada G, Roujeau JC, Cordonnier C, Bagot M, Kuentz M, Wechsler J, Vernant JP: Toxic epidermal necrolysis after bone marrow transplantation: Study of nine cases. J Am Acad Dermatol 1990;23:870–875.
Ferrara JLM, Levy R, Chao NJ: Pathophysiologic mechanisms of acute graft-vs-host disease. Biol Blood Marrow Transplant 1999;5:347–356.
French LE, Tschopp J: Fas-mediated cell death in toxic epidermal necrolysis and graft-versus-host disease: Potential for therapeutic inhibition. Schweiz Med Wochenschr 2000;130:1656–1661.
Viard I, Wehrli P, Bullani R, Scheider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tshopp J, French LE: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490–493.
Correia O, Delgado L, Ramos JP, Resende C, Fleming-Torrinha JA: Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. Arch Dermatol 1993;129:466–468.
Cleach LE, Delaire S, Boumsell L, Bagot M, Bourgault-Villada I, Bensussan A, Roujeau JC: Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 2000;119:225–230.
Kohler S, Hendrickson MR, Chao NJ, Smoller BR: Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease. Am J Surg Pathol 1997;21:988–996.
Zhou Y, Barnett M, Rivers JK: Clinical significance of skin biopsies in the diagnosis and management of graft-vs-host disease in early postallogeneic bone marrow transplantation. Arch Dermatol 2000;136:717–721.
Takeda H, Mitsuhashi Y, Kondo S, Kato Y, Tajima K: Toxic epidermal necrolysis possibly linked to hyperacute graft-versus-host disease after allogeneic bone marrow transplantation. J Dermatol 1997;24:635–641.
Myauchi H, Hosokawa H, Akaeda T, Iba H, Asada Y: T-cell subsets in drug-induced toxic epidermal necrolysis: Possible pathogenic mechanism induced by CD8-positive T cells. Arch Dermatol 1991;127:851–855.
Wehrli P, Viard I, Bullani R, Tshopp J, French LE: Death receptors in cutaneous biology and disease. J Invest Dermatol 2000;115:141–148.
Langley RGB, Walsh N, Nevill T, Thomas L, Rowden G: Apoptosis is the mode of keratinocyte death in cutaneous graft-versus-host disease. J Am Acad Dermatol 1996;35:187–190.
Gilliam AC, Whitaker-Menezes D, Korngold R, Murphy GF: Apoptosis is the predominant form of epithelial target cell injury in acute experimental graft-versus-host disease. J Invest Dermatol 1996;107:377–383.
Klimczak A, Lange A: Apoptosis of keratinocytes is associated with infiltration of CD8+ lymphocytes and accumulation of ki67 antigen. Bone Marrow Transplant 2000;26:1077–1082.
Nimer S, Giorgi J, Gajewski J, Ku N, Schiller G, Lee K, Territo M, Ho W, Feig S, Selch M, Isacescu V, Reichert T, Champlin R: Selective depletion of CD8-positive cells for prevention of graft-versus-host disease following bone marrow transplantation: A randomized controlled trial. Transplantation 1994;57:82–87.
Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondón G, Seong D, Lee M, Gajewski J, Besien KV, Khouri I, Mehra R, Przepiorka D, Körbling M, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin R: CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995;86:4337–4343.
Nagler A, Condiotti R, Nabet C, Naparstek E, Or R, Samuel S, Slavin S: Selective CD4+ T-cell depletion does not prevent graft-versus-host disease. Transplantation 1998;66:138–141.
Fukuda H, Nakamura H, Tominaga N, Teshima H, Hiraoka A, Shibata H, Masaoka T: Marked increase of CD8+S6F1+ and CD8+CD57+ cells in patients with graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994;13:181–185.
Hiraoka A, Kawakami M, Fukuda H, Nakamura H, Karasuno T, Teshima H, Masaoka T: Simple diagnosis of graft-versus-host disease. J Allergy Clin Immunol 1997;100:S70–S72.
Mollet L, Sadat-Sowti B, Duntze J, Leblond V, Bergeron F, Calvez V, Katlama C, Debre P, Autran B: CD8hi+CD57+ T lymphocytes are enriched in antigen-specific T cells capable of down-modulating cytotoxic activity. Int Immunol 1998;10:311–323.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.